Agilent Technologies' stock soared 6.14% in pre-market trading on Thursday, reflecting strong investor sentiment following the company's latest financial results and outlook.

The surge was driven by Agilent reporting better-than-expected fiscal second-quarter results, with adjusted earnings per share of $1.49 beating analyst estimates of $1.41, and revenue of $1.83 billion surpassing expectations of $1.80 billion. Furthermore, the company raised its full-year 2026 adjusted profit forecast to a range of $6.00 to $6.10 per share, up from its prior outlook of $5.90 to $6.04, citing strong demand for its medical tools and laboratory equipment.

Additional factors contributing to the positive momentum include continued growth from GLP-1 drugs, which executives said is driving about 20% year-to-date growth, and positive analyst sentiment, such as TD Cowen raising its price target on the stock.